These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38985649)

  • 21. Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection.
    Thoguluva Chandrasekar V; Venkatesalu B; Patel HK; Spadaccini M; Manteuffel J; Ramesh M
    J Med Virol; 2021 Feb; 93(2):775-785. PubMed ID: 32667699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
    Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
    J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032.
    Brooks KM; Baltrusaitis K; Clarke DF; Nachman S; Jao J; Purswani MU; Agwu A; Beneri C; Deville JG; Powis KM; Stek AM; Eke AC; Shapiro DE; Capparelli E; Greene E; George K; Yin DE; Jean-Philippe P; Chakhtoura N; Bone F; Bacon K; Johnston B; Reding C; Kersey K; Humeniuk R; Best BM; Mirochnick M; Momper JD;
    J Infect Dis; 2024 Oct; 230(4):878-888. PubMed ID: 38839047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral treatment for COVID-19: the evidence supporting remdesivir.
    Richardson C; Bhagani S; Pollara G
    Clin Med (Lond); 2020 Nov; 20(6):e215-e217. PubMed ID: 32863273
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
    Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
    J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
    Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
    SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the Omicron era: A retrospective study.
    Ryu BH; Lee JY; Lee SH
    Medicine (Baltimore); 2024 Jul; 103(29):e39035. PubMed ID: 39029053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case report study of the first five COVID-19 patients treated with remdesivir in France.
    Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
    Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.
    Kamo M; Sogawa R; Shimanoe C
    In Vivo; 2024; 38(4):1841-1846. PubMed ID: 38936945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 35. Update Alert 2: Remdesivir for Adults With COVID-19.
    Kaka AS; MacDonald R; Linskens EJ; Wilt TJ
    Ann Intern Med; 2021 Dec; 174(12):W114-W115. PubMed ID: 34606312
    [No Abstract]   [Full Text] [Related]  

  • 36. Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Rogado J; Gullón P; Obispo B; Serrano G; Lara MÁ
    Eur J Cancer; 2021 May; 148():58-60. PubMed ID: 33735810
    [No Abstract]   [Full Text] [Related]  

  • 37. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.
    Carothers C; Birrer K; Vo M
    Pharmacotherapy; 2020 Nov; 40(11):1166-1171. PubMed ID: 33006138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
    Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
    N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.